LOS ANGELES, CA / ACCESS Newswire / February 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

Farid Adrienne, the Chief Operations Officer of Century Therapeutics , Inc. (NASDAQ:IPSC), recently sold shares of the ...

PHILADELPHIA—Carr Douglas, Senior Vice President of Finance & Operations at Century Therapeutics , Inc. (NASDAQ:IPSC), recently sold 351 shares of the company's common stock. The shares were sold at a ...

LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to ...

PHILADELPHIA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in ...

4 analysts have shared their evaluations of Century Therapeutics (NASDAQ:IPSC) during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find ...

PHILADELPHIA - Century Therapeutics, Inc. (NASDAQ: IPSC), a biotechnology firm with a market capitalization of $77.32 million focused on developing cell therapies for cancer and autoimmune ...

Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. During the same period last year, the firm posted ($0.55) EPS.

LAUSANNE, Switzerland, Jan. 30, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced ...

This page features the latest news about the Century Therapeutics stock. Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B ...